Navigation Links
MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Date:10/21/2010

MOUNTAIN VIEW, Calif., Oct 21 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Thomas P. McCracken as Vice President, Intellectual Property. Mr. McCracken will lead the company's intellectual property program in support of the potential commercialization of the company's lead product candidate, LEVADEX™ orally inhaled migraine therapy, and other product opportunities.

Mr. McCracken has extensive legal experience within the healthcare industry. Most recently, Mr. McCracken was Vice President and Chief Patent Counsel at Durect Corporation, where he was responsible for management, development and creation of all intellectual property assets.  He was previously with PowderJect Pharmaceuticals, where he was responsible for managing IP assets and services across all research and development functions of the company, including vaccines, biopharmaceuticals and medical devices.   Prior to PowderJect, Mr. McCracken was in private patent law practice and specialized in the areas of pharmaceuticals, biotechnology, biomedical engineering and medical devices. His knowledge of the biotechnology field is further supplemented with several years of technical experience in research and development at privately held biopharmaceutical companies, including research activities at the Research Institute of Scripps Clinic.

"Tom joins the company at an ideal time, as his expertise in patent and trademark planning, patent claims structuring and technology licensing will benefit us as we prepare for the potential commercialization of LEVADEX and develop other potential pipeline products," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals.

Mr. McCracken holds a Bachelor's degree in Microbiology from the University of California, San Diego and a Juris Doctor degree from Santa Clara Unive
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 UBM Medica ... a leading online community to help oncologists and other ... available regarding the use of targeted therapies and immunotherapies, ... research and treatment.  Every September, ... way to raise awareness about blood cancers—helping to increase ...
(Date:9/19/2014)... DALLAS , September 19, 2014 ... Market by Equipment Type (Benchtop, Mobile, Industrial, & ... Others), Technology (Tray-style, Manifold, & Rotary) & Geography ... by MarketsandMarkets, defines and segments the lyophilization market ... regions with analyses and projections of the market ...
(Date:9/19/2014)... 2014  Lpath, Inc. (NASDAQ: LPTN ... announced today that it has entered into definitive ... stock and 3,605,042 unregistered warrants in a registered ... registered share of common stock and one unregistered ... stock will be $3.475.  The warrants have an ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... and UBM Canon,s Medical Device Media Group will co-host a ... component selection in an advanced medical system. Dubbed, S ... be led by industry expert Robert Hult. As the ... has nearly 40 years experience in the connector industry, with ...
... 2011 Herborium Group, Inc., (Pinksheets: HBRM) www.herborium.com ... following update today. Dr. Agnes Olszewski, Chairmen ... exciting times for our Company. Firstly, we have continued ... maintaining Herborium, Current Information Status– the highest ...
Cached Medicine Technology:Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar 2Hypertronics Partners with UBM Canon, the Leading Global Medical Device Industry Source, to Co-Host Strategies for Avoiding Device Failure Seminar 3Herborium Group Shareholders Update 2Herborium Group Shareholders Update 3
(Date:9/20/2014)... 6 Minutes to Skinny , a fat loss ... is showing men and women of all ages how they ... using simple 6-minute exercises and easy-to-follow lifestyle tips daily, has ... , “When it comes to losing body fat, unfortunately ... all people,” reports Michaels. “Metabolism plays a big role in ...
(Date:9/20/2014)... 2014 Increases in household, construction ... waste treatment volumes. However, government regulations and higher ... landfill. According to IBISWorld industry analyst Alen Allday, ... aimed at reducing the volume of waste generated, ... recovered.” Still, a large proportion of waste generated ...
(Date:9/20/2014)... September 20, 2014 As testosterone ... in federal court, Bernstein Liebhard LLP notes that ... (FDA) have voted overwhelmingly to recommend that prescription ... be subjected to further study in order to ... published on September 18th by Bloomberg.com, the panel ...
(Date:9/20/2014)... 2014 (HealthDay News) -- As flu season approaches, the ... to get a flu shot and a checkup, according ... care doctor can vaccinate people against the flu, and ... have. Retail stores may provide flu shots for their ... Dr. Jorge Parada, medical director of infection prevention and ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 As ... http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries continue to ... insurer has announced plans to end coverage for ... its website last month, Harrisburg, Pennsylvania-based Capital BlueCross ... 1, 2014. The insurer said its decision was ...
Breaking Medicine News(10 mins):Health News:6 Minutes to Skinny: Review Exposes Craig Ballantyne’s Method to Jump Starting the Metabolism and Blasting Away Body Fat in Just 6 Minutes Per Day 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3
... danger, study warns , MONDAY, June 1 (HealthDay News) ... eat enough to cover their energy output face the ... female athletes in the same circumstances, new research suggests. ... place dancers at higher risk for the "cardiovascular ...
... OTTAWA, June 1 /PRNewswire-FirstCall/ - MDS Nordion, a leading ... of,Canada and Atomic Energy of Canada Limited (AECL) to ... the MAPLE,project to address the current shortage of medical ... (NRU) reactor at Chalk River,Ontario - and to avoid ...
... EMERYVILLE, Calif., June 1 Bayer HealthCare Pharmaceuticals, Inc. ... today announced that the companies have begun enrolling patients ... (sorafenib) tablets in patients with non-squamous non-small cell lung ... treatments. , , "Nexavar has proven efficacy in ...
... Expands Veran,s electromagnetic (EM) navigation for oncology procedures. ... Veran Medical Technologies announced today that it has ... property. Veran secured a worldwide license to ... The Navigation division of Medtronic has developed ...
... twenty-somethings who attend or have graduated from private religious ... peers from public schools, according to sociological research published ... Health and Social Behavior . "This research suggests ... of social, financial and health-related factors that can make ...
... International (NYSE: VRX ) announced today that it ... SGP ) for taribavirin in Japan. In ... and release its last right of refusal on taribavirin under ... pursue partnering arrangements for the rest of the world. ...
Cached Medicine News:Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 2Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 3Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 4Health News:MDS Nordion Urges Government of Canada to Complete MAPLE Project to Address Current Medical Isotope Supply Shortage 5Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 2Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 3Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 4Health News:Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer 5Health News:Veran Medical Technologies Announces Intellectual Property Agreement With Medtronic 2Health News:Religious devotion does not impact abortion decisions of young unwed women 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 2Health News:Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: